No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
INGR240719P120000
- 3.90
- 0.000.00%
15min DelayClose May 21 14:40 ET
0.00High0.00Low
0.00Open3.90Pre Close0 Volume0 Open Interest120.00Strike Price0.00Turnover699.70%IV1.49%PremiumJul 19, 2024Expiry Date2.14Intrinsic Value100Multiplier-4DDays to Expiry1.76Extrinsic Value100Contract SizeAmericanOptions Type-0.5312Delta0.0469Gamma30.22Leverage Ratio-45.7523Theta-0.0001Rho-16.05Eff Leverage0.0048Vega
Intraday
- 5D
- Daily
News
Slowing Rates Of Return At Ingredion (NYSE:INGR) Leave Little Room For Excitement
If EPS Growth Is Important To You, Ingredion (NYSE:INGR) Presents An Opportunity
Ingredion to Release 2024 Second Quarter Financial Results on August 6, 2024
Ingredion Releases 2023 Sustainability Report: Building a Sustainable Future. Together.
Global Pea Protein Ingredients Market Dynamics, Opportunity Analysis and Forecasts 2024-2030 Featuring Roquette Freres Le Romarin, DSM, Ingredion, DuPont De Nemours, ADM, and AGT Food and Ingredients - ResearchAndMarkets.com
United States Animal Feed Market Forecasts From 2024 to 2029 Featuring Cargill, Ingredion, BASF, Alltech, Archer Daniels Midland, and DSM
Comments
Ingredion's dividend is sustainable, backed by profits and cash flow. Its EPS growth and low payout ratio indicate investment in growth. Faster earnings growth would be ideal. It's a good dividend investment candidate, but risks exist.
Should You Buy Ingredion Incorporated (NYSE:INGR) For Its Upcoming Dividend? 1
Despite Ingredion's low PE ratio, the risk of negative growth looms. Investors should ponder on increasing exposure to Ingredion or diversifying. Further research is advised, considering the risks of future negative growth.
1
Analysts' optimism dwindles as they predict a revenue drop while EPS remains steady. The narrow estimate spread suggests easy valuation or strong views on future prospects. The consensus price target remains steady, indicating no major change in business prospects. However, Ingredion's revenues are expected to underperform the wider industry.
Ingredion's lower trading price relative to industry peers coupled with a strong future earnings growth outlook presents an enticing investment opportunity. Other aspects like capital structure require examination for a well-informed decision.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Novo-Nordisk A/S(NVO.US$ - up 13.4%
2. $Eli Lilly and Co(LLY.US$ - up 10.5%
3. $James Hardie Industries(JHX.US$ - up 10.1%
4. $New York Times(NYT.US$ - up 3.3%
5. $POSCO(PKX.US$ - up 2.9%
6. $Fox Corp-B(FOX.US$ - up 2.8%
7. $Fox Corp-A(FOXA.US$ - up 2.8%
8. $West Pharmaceutical Services(WST.US$ - up 2.5...
Gap Ups
1. $Novo-Nordisk A/S(NVO.US$ - up 13.4%
2. $Eli Lilly and Co(LLY.US$ - up 10.5%
3. $James Hardie Industries(JHX.US$ - up 10.1%
4. $New York Times(NYT.US$ - up 3.3%
5. $POSCO(PKX.US$ - up 2.9%
6. $Fox Corp-B(FOX.US$ - up 2.8%
7. $Fox Corp-A(FOXA.US$ - up 2.8%
8. $West Pharmaceutical Services(WST.US$ - up 2.5...
+17
10
Read more